COMP <GO>
IART vs JNJ // RETURN ON INVESTED CAPITAL (ROIC)
Integra LifeSciences Holdings Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: IART 0
— JNJ 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: JNJ
LAST: $12.83 (+4.82%) • MKT CAP: $998.2M
roic
-35.00%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
roic
25.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IART VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IART | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.90% | 67.90% | -17.00 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.11% | 2.97% | -6.08 | JNJ | /fcf-yield <GO> |
| Operating Margin | -30.20% | 34.70% | -64.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -31.60% | 28.50% | -60.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 6.00% | -4.50 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.64 | 5.59 | -4.95 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.8 | 62.1 | -19.28 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $998.2M | $662.49B | -$661.49B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IART REV | JNJ REV | IART GROSS % | JNJ GROSS % | IART FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.64B | $94.19B | 50.9% | 67.9% | -$31.1M | $19.70B |
| FY 2024 | $1.61B | $88.82B | 54.8% | 69.1% | $25.0M | $19.84B |
| FY 2023 | $1.54B | $85.16B | — | — | $140.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IART // BETA —
JNJ // BETA 1.08